On-treatment Biomarkers Can Improve Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer

Richard J. Bownes; Arran K. Turnbull; Carlos Martinez-Perez; David A. Cameron; Andrew H. Sims; Olga Oikonomidou

Disclosures

Breast Cancer Res. 2019;21(73) 

In This Article

Materials and Methods

Patients, Response Criteria, and Samples

The NEO study consists of 50 breast cancer patients with sequentially sampled biopsies at four time points, pre-treatment (PT, 34 samples), 2 weeks on treatment (T2, 12 samples), mid-chemo (TM, 23 samples), and at surgical resection (TS, 24 samples) with three clinically defined response statuses: complete responders (pCR by resection), good responders (tumour volume reduction, but lack of pCR), and non-responders (progressive disease or small tumour volume changes on treatment). Patients were of mixed histological grade and HER2 status; ages ranged from 29 to 76. Patients were primarily treated with 3 cycles of FEC and docetaxel with Herceptin where appropriate. Three patients received paclitaxel, one patient received additional carboplatin, one patient received Epi-cyclophosphamide and paclitaxel, and one patient received docetaxel and cyclophosphamide. Eligible patients were women with histologically confirmed invasive breast tumours and with no evidence of distant metastatic disease, no prior history of malignancy, and fit enough to receive chemotherapy in the opinion of the responsible clinician irrespective of age. All cases were discussed at the breast MDM in Edinburgh Breast Unit at the Western General Hospital, and consensus from this meeting was to be treated with neoadjuvant chemotherapy.

Core needle (16-gauge) biopsies were taken from the primary breast tumours before treatment (PT) and between 10 and 14 days after the first dose (T2) of chemotherapy. A third sample was taken at the mid-chemotherapy point day 20–21 (TM), and finally, a core biopsy was taken from the excision specimen (TS) after it has been removed prior to submission to pathology. Fixed and frozen samples of normal and tumour tissue were collected from all specimens.

Gene Expression Profiling

RNA extraction was performed via Ribo0-RNAseq, and whole transcriptome sequencing was performed with Life Sciences Ion AmpliSeq™ Transcriptome Human Gene Expression Kit. This generated greater than 8 M reads per sample with an average of more than 90% valid reads for 12,365 targeted genes. Most analyses were performed in R (http://www.r-project.org) using packages available through CRAN (http://cran.r-project.org/) and Bioconductor (http://www.bioconductor.org/). Outside of the R environment, the stand-alone application Multiple Experiment Viewer (http://mev.tm4.org/) was utilised for pairwise ranked product feature selection, and DAVID (https://david.ncifcrf.gov/) was used for pathway identification. Additionally, the python package scikit-learn[14] was used for unsupervised clustering analysis. Ninety-seven samples were analysed over 13 AmpliSeq chips, but no systematic batch effects were evident and no batch correction was performed within the training data. Gene expression data for the NEO study has been made publicly available at the NCBI GEO data repository under accession GSE122630.

The I-SPY 1 Trial is composed of patients with invasive breast cancer > 3 cm, or at least one tumour-positive axillary lymph node.[11] Patients were treated with an anthracycline-based chemotherapy followed by taxanes.[11] Samples were normalised and corrected for background red/green signal; Bioconductor R packages marray and limma[15] were used to this end. From the original 221 patients, only 36 had matching pre- and on-treatment samples, and 39 had matching biopsy and excision samples; pathological complete response was used for response criteria. Pairwise gene expression was handled with SAM and follow-up analysis with Ingenuity Pathway Analysis from QIAGEN Bioinformatics. I-SPY 1 Trial data is hosted at NCBI GEO under accession GSE32603.[11]

Statistical Analysis Methods

Principal component analysis (PCA) was performed on unsupervised gene lists to reduce dimensionality and visualise differences in response at all times and to identify present differences between patient treatment statuses. Local Fisher discriminant analysis (LFDA)[16] was used at each time point to determine if the response groups could be distinguished with treatment time with a semi-supervised clustering approach, concurrently with class advised K-means clustering. LFDA is a form of supervised dimensionality reduction that maximises between-class scattering and minimises within class scatter, and is a refined version of normal Fisher discriminant analysis;[16] this exploratory analysis was used in order to visualise comparative differences in treatment time, not as a means of feature selection. Pair-wise significance analysis of microarrays[17] using the siggenespackage in R was used to consider the consistency of differentially expressed genes due to treatment in the sequential patient-matched samples. Rank Product analysis was used to identify differentially expressed genes between response classes at each time point. Successive levels of standard p value (0.05, 0.01, 0.001), without correction for multiple testing, were used in order to determine the number of differentially expressed genes, and at lower p values which the time points had the most strongly differentiating genes. Significance analysis of microarrays was also performed using varying false discovery rates (1%, 5%, 10%) to try to identify common differentially expressed genes between responders and non-responders across both datasets at each time point. Gene score enrichment analysis was used to validate the time point selection by looking for the highest number of enriched pathways. The gene list from the most differential time point (TM) using the NEO dataset was extracted and used in a random forest model (10,000 trees, m-try as the square root of the feature number) using pCR status as the class label (clinician-identified pCR and non-pCR). The most deterministic genes for class prediction were fed into a classification and regression tree in order to produce a maximally reduced and repeatable model; this methodology is further described by Turnbull et al..[7] The CART decision tree was applied to the NEO dataset for training and tested in the independent I-SPY 1 dataset using the same cut-points determined by mean-centring the datasets. This protocol was repeated using the gene list from the pre-treatment only samples, using the same p values and tree configurations for selection. Survival analysis was performed at different time points using the log-rank test. Intrinsic subtypes, Mammaprint, and risk or relapse scores were estimated from the gene expression data using the GeneFu R package.[18]

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....